High-throughput screening from FDA-approved drug library using cell viability assay showed that auranofin (AUR) had a much more striking anti-cancer efficacy in ChaC1-overexpressed Huh7 cells than that in control cells (Fig. 1A, B), suggesting that AUR is one of the GSH-sensitive drugs. This evidence concerns the gene CHAC1 and cancer.